For instance, high levels of an angiogenesis gene signature score at baseline, low baseline serum angiopoietin-2, or early induction of hypertension during treatment could identify responders and could help in a better selection of patients for future anti-VEGFR therapies (19). This evidence concerns the gene KDR and Hypertension.